Search Bar & Filters
Found 294 Actively Recruiting clinical trials
Actively Recruiting
Researchers are comparing the pathological and cancer-related outcomes of two surgical methods Transurethral En Bloc Resection of Bladder Tumor ERBT and Transurethral Resection of Bladder Tumor TURBT in patients with large bladder tumors larger than 2.5 cm. This phase 3 trial aims to evaluate the recurrence rates after one year for these two procedures in treating non-muscle invasive bladder cancer NMIBC and transitional cell carcinoma TCC. The study is randomized and conducted without masking. Participants are assigned to one of two groups those undergoing ERBT surgery, which involves removing the bladder tumor in one piece using any energy source, and those receiving the standard TURBT surgery using mono or bipolar electrocautery. The primary outcome is the recurrence of bladder tumors at 12 months. Secondary outcomes include the presence of detrusor muscle during surgery, diagnosis of muscle-invasive cancer based on pathology, surgical complications within 30 days, and any conversion to a different surgical technique during the procedure. During the study, participants will be monitored perioperatively and followed for one year to assess tumor recurrence and other outcomes. Researchers will collect data on surgical results, pathology findings, and any complications. The trials total duration for each participant includes the surgery and a follow-up period of 12 months to evaluate the primary endpoint of recurrence and other safety and diagnostic measures.
Actively Recruiting
This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.
Actively Recruiting
This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.
Actively Recruiting
Researchers are exploring new treatments for high-risk non-muscle invasive bladder cancer HR NMIBC, a type of cancer that affects the bladder lining without spreading to the bladder muscle or beyond. This research focuses on the safety and tolerability of MK-3120, a study drug, following the standard tumor removal procedure called transurethral resection of the bladder tumor TURBT. The study is a Phase 12 clinical trial investigating MK-3120 in people with HR NMIBC who are either Bacillus Calmette-Gurin BCG-nave or BCG-exposed. Participants will receive MK-3120 through intravesical administration, meaning the drug is delivered directly into the bladder. The treatment schedule begins with once-weekly doses for the first 6 weeks, followed by once-monthly doses for 9 months. This dosing plan aims to evaluate the drugs safety and effects over a period that includes the initial intensive phase and a maintenance phase. During the study, participants will be monitored closely for dose-limiting toxicities and adverse events up to about 24 months. Researchers will assess if participants discontinue treatment due to side effects within roughly 12 months. The main goal is to evaluate the safety profile of MK-3120 and observe its complete response rate up to approximately 3 months. Participants can expect regular assessments, including safety monitoring and treatment visits, throughout their involvement in the trial lasting several months to years.
Actively Recruiting
Researchers are investigating new treatment options for people with certain advanced or metastatic solid tumors that have alterations in the KRAS gene. This Phase 1 trial aims to evaluate the safety and tolerability of the drug MK-4716 when taken alone or in combination with other treatments. The study focuses on understanding possible side effects and how well participants tolerate these therapies. Participants will receive MK-4716 either by itself at different dose levels and schedules, or in combination with Pembrolizumab or Cetuximab, both given by intravenous infusion. The study has multiple groups running in parallel, each receiving one of these treatment approaches. MK-4716 is taken orally, and the combinations involve intravenous administration of the other drugs. During the trial, participants will be closely monitored for any dose-limiting toxicities and adverse events up to approximately 4 years. Researchers will assess drug levels in the blood at set timepoints to understand how MK-4716 behaves in the body. Participants will undergo regular evaluations including safety checks and measuring disease status. The study duration may extend over several years to gather long-term safety and response information.
Actively Recruiting
Researchers are evaluating treatments for high-grade serous and certain other types of ovarian cancer that tend to grow and spread quickly. This study focuses on advanced cancers that started in the ovaries, lining of the belly, or fallopian tubes. The trial aims to assess the safety, tolerability, and response of a study drug called Raludotatug Deruxtecan R-DXd, which is an antibody drug conjugate designed to target and destroy cancer cells. This research includes a dose escalation phase followed by an expansion phase using the recommended dose. Participants will receive R-DXd through intravenous infusions every three weeks, often combined with other anticancer treatments such as carboplatin, paclitaxel, bevacizumab, pembrolizumab, or MK-2010. These combinations vary across different groups in the study, with some receiving up to six cycles of chemotherapy drugs over approximately four months, and others receiving immunotherapy or targeted therapy for longer periods, up to two years. The study allows continued treatment with R-DXd until disease progression or discontinuation. During the trial, participants will undergo regular clinical assessments including imaging scans to measure tumor response, monitoring for side effects, and laboratory tests. The main outcomes include tracking dose-limiting toxicities, adverse events, treatment discontinuations due to side effects, objective tumor response, and progression-free survival. Follow-up may continue for up to several years to evaluate longer-term effects and survival. The total duration of participation depends on treatment response and tolerability.
1-10 of 294
1